-
AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth
•
UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca’s strong pipeline and…
-
Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
•
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical drug candidate QLS12004 has obtained tacit clinical trial approval. This marks a significant step forward in the development of new treatments for solid tumors, including advanced breast cancer, which is the leading malignant cancer affecting…
-
Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for a previously planned initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This decision comes amidst considerations of the current market situation and corporate development planning. Reasons for TerminationSino Bio cited…
-
Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions
•
China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation, leveraging their respective advantages and integrating resources to comprehensively cooperate in the area of biochemical immune diagnosis overall solutions. This strategic collaboration aims to enhance the market presence of both companies in the diagnostic sector.…
-
GenScript ProBio Partners with Bio Immunitas for hRPP Platform
•
Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a long-term partnership with UK-based Bio Immunitas, a firm built around a proprietary human Recombinant Protein Platform (hRPP). This strategic collaboration aims to accelerate Bio Immunitas’s manufacturing capabilities from the lab to clinic, including IND-enabling CMC…
-
ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment
•
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011 IT, has produced positive signs of efficacy as a treatment for melanoma in late-stage patients who have failed previous immunotherapy. In a Phase II clinical study conducted in China and the United States, monotherapy treatment…
-
Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs
•
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and oncology, has announced the completion of a Series D financing round at close to RMB 300 million (USD 44.18 million). This significant funding round was led by Hongfu Investment, with contributions from Jihan Capital, Hainan…
-
Neurodawn Completes Series A+ Financing for CNS Drug Development
•
Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has announced the completion of a Series A+ financing round in excess of RMB 100 million (USD 14.73 million). The round was led by China Merchants Health, with existing investor Simcere Pharmaceutical Group (HKG: 2096) participating.…
-
Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment and dosing in the Phase Ib REFINE study for its drug candidate STC3141 in sepsis in Australia and Belgium. The first data readout is expected in four months’ time, marking a significant milestone in the…
-
Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering
•
Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional approval from the SIX Swiss Exchange to make a public offering of an undisclosed amount of Global Depositary Receipts (GDR) on the bourse. This marks a significant step in the company’s international expansion and capital…
-
Teddy Clinical Research Lab Partners with Cerba Research for Global Services
•
China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244) and Tigermed (SHE: 300347, HKG: 3347), has struck a partnership with Belgium-headquartered Cerba Healthcare’s subsidiary Cerba Research. The two companies will set up a JV in Wuxi, Jiangsu Province, China, marking a significant expansion of…
-
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
•
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply issues, prompting the company to seek additional production and supply agreements. The latest deal was struck with Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), following a similar agreement with Zhejiang Huahai Pharmaceutical Co., Ltd (SHA:…
-
Macrolux Secures Series A Funding for Endoscopy Solutions
•
Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB 100 million (USD 14.75 million) in a Series A financing round. This significant capital injection will support the company’s efforts to provide solutions better tailored to customer needs globally. Financing DetailsThe Series A round was…
-
Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
•
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment under the terms of a cooperation deal with Bayer (ETR: BAYN). The payment is related to Hua’s first-in-class glucokinase activator (GKA) dorzagliatin, which was approved in China in October 2022 for the treatment of metformin-tolerant…
-
SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza
•
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017, has announced that a market approval filing has been made in Hong Kong for its Danyelza (naxitamab) in recurrent or refractory high-risk neuroblastoma. This marks a significant step in the global expansion of this innovative…
-
Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs
•
Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing round led by Efung Fund, with participation from True Trust Investment. The proceeds will be used to advance large animal experiments, investigator-initiated trials (ITT), and Investigational New Drug (IND) filing preparations. This…
-
Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development
•
Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. This significant capital injection was led by Waldorf Capital, with contributions from Hainayourong Investment and Jiagengxin Capital. The proceeds will be directed towards CT X-Ray tube…
-
Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a partnership with compatriot firm ReviR Therapeutics, an artificial-intelligence (AI) and gene tech-powered start-up. The collaboration aims to utilize ReviR’s in-house developed AI drug research and development (R&D) platform and targeted RNA technology to conduct research…
-
Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact
•
Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial report for the three-month period ending December 31, 2022. Global revenues were down 4.5% to EUR 5.077 billion (USD 5.5 billion), primarily reflecting the slowing demand for COVID-19 antigen testing. Business Group PerformanceExcluding COVID-19 antigen…
-
Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its fiscal year 2022, which ended December 31, 2022. The firm’s global revenues over the 9-month period reached JPY 1.164 trillion (USD 8.79 billion), marking a 17.3% year-on-year (YOY) growth. Top Performers and Sales DataAstellas’ top…
